News & Events

Learn about what's new with CMC Biologics

CMC Biologics Enters into Commercial Supply Agreement with Portola Pharmaceuticals for Manufacturing of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa


Seattle, Wash. – July 2, 2014 CMC Biologics, Inc., a global leader in process development and contract manufacturing, today announced that it has entered in to a Commercial Supply Agreement with Portola Pharmaceuticals, a biopharmaceutical company for the development of andexanet alfa, a potential first-­ in class Factor Xa inhibitor antidote in Phase 3 ANNEXATM (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. Andexanet alfa is designed to reverse the anticoagulation activity of Factor Xa inhibitor‐treated patients who are experiencing a major bleeding episode or who require emergency surgery.

Follow Us
Join us on LinkedIn Follow us on Twitter